Elsa Science
Elsa Science is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Elsa Science.
Elsa Science is a company.
Key people at Elsa Science.
Elsa Science is a Swedish digital therapeutics company founded in 2017 that develops software-driven cognitive behavioral therapy (CBT) interventions via a mobile app companion.[1][2] The app targets patients with chronic conditions like rheumatoid arthritis (RA), enabling them to track symptoms, habits, and medication adherence, while providing personalized self-management plans endorsed by healthcare professionals to improve quality of life between doctor visits.[1][4] Serving both consumers (B2C) and businesses like healthcare providers and pharma (B2B), it addresses the gap in understanding patients' daily lives, with early seed funding from investors including Norrsken, HealthCap, and Inventure, and backing from the European Investment Fund (EIF) for product development.[1][2] As of recent data, the Stockholm-based team numbers 11-50 employees (with one source noting 21), showing steady growth in the medtech sector.[1][2]
Elsa Science was co-founded in 2017 by Sofia Svantesson (CEO), who has a background in digital solutions focused on human-centered tech, alongside rheumatology professor Lars Klareskog and epidemiology professor Lars Alfredsson.[1][2] Svantesson's fascination with mobile tech's potential to solve real-world problems in healthcare drove the idea: with nearly 20 million people living with RA globally and over a million new cases yearly, she aimed to bridge the divide between clinical visits and everyday self-management.[1] The company emerged from this tech-science collaboration, quickly securing InnovFin Equity financing via EIF and Norrsken to fuel product development, marking early traction in digital therapeutics for chronic illness.[1][2]
Elsa Science rides the wave of digital therapeutics and patient empowerment in medtech, capitalizing on rising chronic disease prevalence (e.g., RA's global burden) and the shift toward value-based care.[1] Timing aligns with post-2017 growth in mobile health apps, accelerated by demands for remote monitoring amid healthcare strains, where real-world data fills gaps in episodic clinical care.[1][2] Favorable market forces include pharma's interest in patient adherence analytics and regulatory support like EIF's InnovFin for EU SMEs, amplifying its influence in Sweden's vibrant healthtech scene (via Norrsken ecosystem).[1][2] By enabling better outcomes for the chronically ill, Elsa contributes to broader ecosystem shifts toward preventive, data-driven selfcare, potentially influencing scalable models for other diseases.[3]
Elsa Science is poised for expansion beyond RA into wider chronic care, leveraging its seed momentum, EIF-backed development, and clinician-validated tech to capture growing digital health demand.[1][2] Trends like AI-enhanced personalization and integrated pharma partnerships will shape its path, potentially driving B2B scaling and global reach from its Swedish base. Its influence may evolve from niche RA support to a key player in redefining selfcare ecosystems, delivering on the founding vision of fuller lives for millions—echoing Svantesson's human-tech fusion that sparked it all.[1]
Key people at Elsa Science.
